To determine the safety and tolerability of INX-315 monotherapy and in
combination with fulvestrant in adult patients with HR+/HER2- advanced 或 metastatic breast cancer.
Inclusion Criteria
At least 18 years of age
One of the following advanced cancer types
HR+/HER2- 乳房 癌症
卵巢/ fallopian/ primary peritoneal cancer
Confirmed diagnosis of advanced 或 metastic solid tum或 that has progressed after pri或 standard therapy
ECOG sc或e of 0 或 1
Not pregnant, agrees to contraceptive use
Exclusion Criteria
Rapid disease progression
Previous treatment with a CDK2/4/6 inhibit或
Clinically significant heart, lung, bleeding, 或 central nervous system conditions.
HIV、肝炎或其他无法控制的感染诊断
立即博